Omeprazole 40 MG + Famotidine 40 mg + Telotristat ethyl 250 mg
Phase 1Completed 0 watching 0 views this week💤 Quiet
28
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Drug-drug Interaction
Conditions
Drug-drug Interaction
Trial Timeline
Sep 21, 2017 → Nov 7, 2017
NCT ID
NCT03302845About Omeprazole 40 MG + Famotidine 40 mg + Telotristat ethyl 250 mg
Omeprazole 40 MG + Famotidine 40 mg + Telotristat ethyl 250 mg is a phase 1 stage product being developed by Lexicon Pharmaceuticals for Drug-drug Interaction. The current trial status is completed. This product is registered under clinical trial identifier NCT03302845. Target conditions include Drug-drug Interaction.
Hype Score Breakdown
Clinical
10
Activity
5
Company
5
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03302845 | Phase 1 | Completed |
Competing Products
15 competing products in Drug-drug Interaction